The European Medicines Agency (EMA) published current results of analysis of rare cases of blood clots tied with low level of platelets of people, who were vaccine with AstraZeneca vaccine against Covid-19 (currently Vaxzevria) as the EMA reported.
“Independent external experts with a range of medical specialities, including haematologists, neurologists and epidemiologists, discussed specific aspects such as possible mechanisms, whether underlying risk factors could be identified and what additional data are needed to further characterise the observed events and the potential risk. At present the review has not identified any specific risk factors, such as age, gender or a previous medical history of clotting disorders, for these very rare events,” the message said.
Thus, the cause-and-effect link of these side effects with the vaccine is not proved but it is possible and further analysis continues.
Earlier, the EMA stated it believes that advantages of AstraZeneca vaccine in prevention Covid-19 with allied risk of hospitalization and risk outweigh the risks of side effects. The vaccinated people should be aware of possible rare blood clots types. If they have proper symptoms pointing at problems with blood coagulation, they should urgently request for medical aid and report medical employees about recent vaccination.
Due to the blood clots, some countries stopped the use of the AstraZeneca vaccine; particularly, Denmark, Austria, Estonia, Lithuania, Luxembourg, Latvia and Cyprus. Norway is not an EU member but it also stopped the use of AstraZeneca. Later, Bulgaria, Thailand and Romania joined this list. Soon, Ireland and the Netherlands also refused fro AstraZeneca’s use.
Germany, France and Italy also confirmed the refusal of the AstraZeneca vaccine.
In Norway, three medics were hospitalized with blood clots. While a woman died after AstraZeneca shot in Croatia. In Spain, a 43-year-old teacher, who had never pathologies earlier, was vaccinated by AstraZeneca and died from cerebral hemorrhage.
As of now, Canada does not vaccinate people under the age of 55 with AstraZeneca. According to Vice-chair of the NACI Shelley Deeks, there is substantial uncertainty about the benefit of providing AstraZeneca Covid-19 vaccines to adults under 55 given the potential risks.
At the end of March, AstraZeneca vaccine was renamed as Vaxzervia.